Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. Currently, close to 60 industry players are actively offering NGS kits for preparing DNA / RNA libraries. Players Engaged in the Domain.

Genetics 52

Genetics DNA RNA Reagent 52

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. Concluding Remarks.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

pharmaphorum

FEBRUARY 3, 2021

“A recent report indicates that autologous T cells that carry multiple CRISPR-Cas9-mediated genetic modifications designed to improve persistence and efficacy can be safely administered to patients with refractory cancer, providing an important step forward in the use of CRISPR in immune cell therapies”.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Drug Discovery World

DECEMBER 15, 2022

Gene editing tools such as zinc finger nucleases, transcription activator-like effector nucleases (TALEN) and clustered regularly interspaced short palindromic repeat (CRISPR) nucleases have been heralded for their enormous potential to treat diseases and genetic disorders. In one example, Choi et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

JUNE 6, 2023

“We’re still seeing those at the meeting at the moment”, he said, and thinks they still hold great promise for patients the better we understand patient genetics. He said: “We saw patient transcriptomics from CRUK this week, particularly all the data coming out from the TRACERx study, looking at the evolution of lung cancer.

Protein 52

Protein DNA RNA Research 52